Clinical responsibilities include oversight of biostatistical and data management activities related to the design

Document Sample
Clinical responsibilities include oversight of biostatistical and data management activities related to the design Powered By Docstoc
					                       DREW WATSON, Ph.D., MBA
                              1950 Noel Drive • Los Altos, California 94024 • Home (650) 962-9444
                     Mobile (650) 888-7302 • e-mail Drew@DrewWatson.com • Web: www.DrewWatson.com

    EXPERIENCE
    VP, Biostatistics & Data Management                                                                    February 2003 - Present
    Genomic Health, Inc.                                                                                  Redwood City, California
    Genomic Health, Inc. is an oncology-based health care services company providing individualized genomic analysis of tumor
    biopsies. Management responsibilities include supervision of a group of 20 statisticians and data managers with direct
    reporting relationship to the Chief Medical Officer/Executive VP of Development. Clinical responsibilities include
    oversight of biostatistical and data management activities related to the design, analysis, and regulatory submission of large-
    scale oncology trials in support of the development of pharmacogenomic tests and predictive algorithms. Non-clinical
    activities include the development, validation and commercialization of high-throughput assays utilizing RNA extracted from
    fixed paraffin embedded tissues.

    Founder & Chief Executive Officer                                                                           June 2001 - Present
    Novation Biosciences (acquired by Agilent Technologies)                                                   San Mateo, California
    Founder and CEO of a computational biology company aimed at lead drug discovery and quality control of high-throughput
    biological systems. Raised $1.6M in Series A financing from investors including Accenture Venture Capital, Mobius Venture
    Capital (formerly Softbank Venture Capital), GameChange LLC, and Evercore. Acted as Chief Scientific Officer responsible
    for the scientific development of the Company’s primary products including
    Qualifier™ - a quality/performance management system for high-throughput biological systems.
    Curator™ -         a biological text mining solution for drug discovery.
    Predictor™ - a lead discovery platform that utilizes both proprietary numerical, structural and semantic (text) data to
                       predict key characteristics of lead compounds.

    VP of Quantitative Biology & General Manager of Incyte Microarray Systems                                           1997–2001
    Incyte Genomics                                                                                            Palo Alto, California
    As General Manager, provided leadership, vision, strategic direction and operational excellence in running a division of 150
    employees involved in the commercialization of gene and protein expression technologies. Also responsible for corporate
    development activities including strategic and business management, technology assessment, licensing, intellectual property,
    and M&A activities. Handled staffing, planning, operations, marketing and customer support activities with direct P&L
    responsibility for a $20M organization. As VP of Quantitative Biology provided guidance in the development of statistical,
    bioinformatics and quantitative methods for target identification and the analysis of genomic sequence and expression data.
    Associate Director, Biostatistics                                                                                   1994–1997
    Chiron Corporation (acquired by Norvartis)                                                                Emeryville, California
   Managed a biostatistical and data management department responsible for providing leadership in the discovery,
    development, manufacture and marketing of biopharmaceutical products including vaccines, therapeutics and molecular
    diagnostic devices. Clinical support responsibilities at Chiron included overseeing statistical and clinical data management
    activities and personnel as well as development of analysis plans, study workbooks and summary reports for the successful
    submission of FDA IND, NDA, 510(k) and PMA applications. Non-clinical responsibilities involved providing biostatistical
    support to drug discovery, computational chemistry, bioinformatics, clinical research, assay development, process
    development, pharmacology, manufacturing, regulatory affairs, marketing, corporate compliance and quality assurance.

    Manager, Experimental Statistics                                                                                    1992–1994
    Syntex Pharmaceuticals (acquired by Roche Biosciences)                                                     Palo Alto, California
   Provided management and statistical expertise for pharmaceutical research activities. Instrumental in the establishment of an
    Experimental Statistics Department responsible for R&D, pharmaceutical research, clinical development, pharmacology and
    assay development activities. Responsibilities included the application of statistical experimental design, optimization,
    robustness, reliability and statistical quality control methods for process improvement.

                1950 Noel Drive • Los Altos, California 94024 • Home (650) 962 -9444
        Cell (650) 888-7302 • e-mail Drew@DrewWatson.com • Web: www.DrewWats on.com
      Drew Watson, Ph.D., MBA


    Founder & Principal Management Consultant                                                                          1985–1992
    Process Plus, Inc.                                                                                        Los Altos, California
   Founder and principal management consultant for Process Plus Inc. - a management consulting firm. Obtained over ten
    years’ management experience under the guidance of the late late Dr. W. Edwards Deming - “Father of the Japanese
    Industrial Revolution.” Consulted to industries as diverse as aerospace, biotechnology, electronics, biopharmaceutical and
    health care. Clients included Hewlett-Packard (nine divisions), Dow Chemical, Applied Materials, NEC, Intel, 3-Com, Siltec,
    Printed Circuit Builders, Computer Products Inc., Connector Technology Inc., Conejo Circuits and Armstrong World
    Industries.

    Senior Statistician                                                                                                1980–1985
    Hewlett-Packard Corporation                                                                               Palo Alto, California
   Provided management and statistical support to nine divisions, including the printed circuit and personal computer divisions.
    Supported several other divisions, including the HP-3000, instrumentation and medical products divisions. Introduced
    Hewlett-Packard's first quality improvement program based on the philosophies of Dr. W. Edwards Deming. Implemented
    Hewlett-Packards first just-in-time manufacturing system.

    EDUCATION
    1998  Golden Gate University, Los Altos, California
          MBA; G.P.A. – 4.0
    1990       University of California, Los Angeles, California
               Ph.D., Biostatistics – Advisor: Robert Elashoff, Ph.D.; G.P.A. – 3.8
    1984       Stanford University, Stanford, California
               M.S., Computational Statistics – Advisor: Jerome Friedman, Ph.D.; G.P.A. 3.5
    1980       California State University, Hayward, California
               B.S., Statistics; G.P.A. – 3.5

    AWARDS & RECOGNITION
    1990       UCLA, School of Public Health, Los Angeles, California
               Ruth F. Richards Award for outstanding academic achievement, character, leadership, extracurricular
               involvement and service to the community.
    1988       California State Superior Court, Santa Clara, California
               Recognized as an expert witness in the fields of statistics and statistical quality control.
    1981       Stanford University, Department of Statistics, Stanford, California
               Honors Cooperative Program: Selected by Stanford University and Hewlett-Packard Corporation to pursue
               graduate education at Stanford University.
    1978       Lawrence Livermore National Laboratory (LLNL), Livermore, California
               Student internship in mathematical statistics.




             1950 Noel Drive • Los Altos, California 94024 • Home (650) 962 -9444
       Cell (650) 888-7302 • e-mail Drew@Novationbio.com • Web: www.DrewWatson.com

                                                              PAGE 2 OF 5
  Drew Watson, Ph.D., MBA


PUBLICATIONS
Cronin M., Sangli C., Liu ML, Pho M., Dutta D., Nguyen A., Jeong J., Wu J., Langone K., Watson D.,
  Analytical Validation of the Oncotype DX Genomic Diagnostic Test for Recurrence Prognosis and Therapeutic Response
  Prediction in Node-Negative, Estrogen Receptor–Positive Breast Cancer, Paper accepted for publication, Clinical
  Chemistry.
Mina L, Soule SE, Badve S, Baehner FL, Baker J, Cronin M, Watson D, Liu ML, Sledge GW Jr, Shak S, Miller KD.,
  Predicting Response To Primary Chemotherapy: Gene Expression Profiling Of Paraffin-Embedded Core Biopsy Tissue,
  Breast Cancer Research Treat. (Published ahead of print Oct 13, 2006).
Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, Cronin M, Baehner FL, Watson D, Bryant J, Costantino JP, Geyer CE Jr,
  Wickerham DL, Wolmark N., Gene Expression And Benefit Of Chemotherapy In Women With Node-Negative,
  Estrogen Receptor-Positive Breast Cancer. Journal of Clinical Oncology. 2006 Aug 10;24(23):3726-34.
Habel LA, Shak S, Jacobs MK, Capra A, Alexander C, Pho M, Baker J, Walker M, Watson D, Hackett J, Blick NT,
  Greenberg D, Fehrenbacher L, Langholz B, Quesenberry CP. A Population-Based Study Of Tumor Gene Expression
  And Risk Of Breast Cancer Death Among Lymph Node-Negative Patients., Breast Cancer Research. 2006;8(3).
Gianni L, Zambetti M, Clark K, Baker J, Cronin M, Wu J, Mariani G, Rodriguez J, Carcangiu M, Watson D, Valagussa P,
  Rouzier R, Symmans WF, Ross JS, Hortobagyi GN, Pusztai L, Shak S., Gene Expression Profiles In Paraffin-Embedded
  Core Biopsy Tissue Predict Response To Chemotherapy In Women With Locally Advanced Breast Cancer. Journal of
  Clinical Oncology. 2005 Oct 10;23(29):7265-77.
Esteva FJ, Sahin AA, Cristofanilli M, Coombes K, Lee SJ, Baker J, Cronin M, Walker M, Watson D, Shak S, Hortobagyi
  GN., Prognostic Role Of A Multigene Reverse Transcriptase-PCR Assay In Patients With Node-Negative Breast Cancer
  Not Receiving Adjuvant Systemic Therapy. Clinical Cancer Research. 2005 May 1;11(9):3315-9.
Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER,
  Wickerham DL, Bryant J, Wolmark N., A Multigene Assay To Predict Recurrence Of Tamoxifen-Treated, Node-Negative
  Breast Cancer., New England Journal of Medicine. 2004 Dec 30;351(27):2817-26.
Evertsz E., Gupta R., Starink P. & Watson D., Technology and Applications of Gene Expression Microarrays, Microarray
  Biochip Technology, BioTechniques Book Division, Eaton Publishing, Natick, Massachusetts, 2000.
Watson G. and Minor J., Statistical Methods for Molecular Diagnostics, Proceedings of the Biopharmaceutical Section,
 American Statistical Association, 1997.
Minor J., Namini H. & Watson G., Generalized Ridge Analysis with Application to Population Pharmacokinetics/
  Dynamics, Journal of Biopharmaceutical Statistics, 6(1), 105-114, 1996.
Watson G. and Dahl T., Analysis of the Stability Properties of Drug Formulation Through the Use of Neural Networks,
 Proceedings of the Biopharmaceutical Section, American Statistical Association, 68-73, 1993.
Watson G. and Elashof R., Nonparametric Influence Diagnostics for the Survivor Function, Technical Report, Department
 of Biomathematics, University of California, Los Angeles, CA, 1990.
Watson G., Influential Observations in Survival Models with Censored Data, Technical Report, Department of
 Biomathematics, University of California, Los Angeles, CA, 1990.




         1950 Noel Drive • Los Altos, California 94024 • Home (650) 962 -9444
   Cell (650) 888-7302 • e-mail Drew@Novationbio.com • Web: www.DrewWatson.com

                                                    PAGE 3 OF 5
  Drew Watson, Ph.D., MBA


POSTERS & PRESENTATIONS
Watson D, Palmer G, Baker J, Shak S., The Impact on the Recurrence Score Due to Patient Variation in the Quantitative
   Expression of Individual Genes or Gene Groups, Presented at: 29th Annual San Antonio Breast Cancer Symposium.
   December 14-17, 2006. San Antonio, TX. Abstract #6039.
Kim C, Tang G, Baehner FL, Watson D, Costantino JP, Paik S, Shak S, Wolmark N., A Comparison of Estrogen Receptor
   (ER) Measurement by Three Methods in Node-Negative, Estrogen Receptor (ER)-Positive Breast Cancer: Ligand Binding
   (LB), Immunohistochemistry (IHC), and Quantitative RT-PCR., Presented at: 29th Annual San Antonio Breast Cancer
   Symposium. December 14-17, 2006. San Antonio, TX. Abstract #3116
Shak S, Baehner FL, Palmer G, Ballard JT, Baker J, Watson D., Relationship Between Proliferation Genes and Expression of
   Hormone and Growth Factor Receptors: Quantitative RT-PCR In 10,618 Breast Cancers. Presented at: 29th Annual San
   Antonio Breast Cancer Symposium. December 14-17, 2006. San Antonio, TX. Abstract #6111.
Shak S, Baehner FL, Palmer G, Ballard JT, Baker J, Watson D., Subtypes of Breast Cancer Defined by Standardized
   Quantitative RT-PCR Analysis of 10,618 Tumors, Presented at: 29th Annual San Antonio Breast Cancer Symposium.
   December 14-17, 2006. San Antonio, TX. Abstract #6118.
Baehner FL, Habel LA, Quesenberry CP, Capra A, Tang G, Paik S, Wolmark N, Watson D, Shak S., Quantitative RT-PCR
   Analysis of ER and PR by Oncotype DX Indicates Distinct and Different Associations With Prognosis and Prediction of
   Tamoxifen Benefit, Presented at: 29th Annual San Antonio Breast Cancer Symposium. December 14-17, 2006. San
   Antonio, TX. Abstract #45.
Cronin M, Sangli C, Liu ML, Pho M, Dutta D, Nguyen A, Jeong J, Wu J, Clark K, Watson D., Analytical Validation For The
   Oncotype DX Breast Cancer Assay, a High Complexity, Multi-Analyte Molecular Diagnostic Test Service, Presented at:
   Association for Molecular Pathology 2006 Annual Meeting. November 16-19, 2006. Orlando, Florida. Poster #ST23.
O'Connell MJ, Paik S, Yothers G, Costantino JP, Cowens JW, Clark KM, Baker J, Hackett J, Watson D, Wolmark N.,
   Relationship Between Tumor Gene Expression and Recurrence in Stage II/III Colon Cancer: Quantitative RT-PCR Assay
   Of 757 Genes in Fixed Paraffin-Embedded (FPE) Tissue, Presented at: 42nd Annual Meeting of the American Society of
   Clinical Oncology. June 2-6, 2006, Atlanta, GA. Abstract #3518.
Bitterman P, Watson D, Cronin M, Mosquera JM, Cobleigh M, Baehner R, Shak S, Baker J, Comparison Of ER, PR, HER2,
   And Ki-67 Quantitative Expression in Formalin-Fixed, Paraffin-Embedded Breast Carcinomas by RT-PCR with Protein
   Expression By Immunohistochemistry, Presented at: United States and Canadian Academy of Pathology Annual Meeting.
   March 6 - 12, 2004. Vancouver, British Columbia. Abstract #83.
Cronin M, Watson D, Dutta D, Liu ML, Pho M, Baehner R, Esteban J, Baker J, Shak S, Reproducibility of Quantitative
   Gene Expression Analysis by a New RT-PCR Assay Using Fixed Paraffin-Embedded Tissues: A Molecular Tomographic
   Scanning Study, Presented at: United States and Canadian Academy of Pathology Annual Meeting. March 6 - 12, 2004.
   Vancouver, British Columbia. Abstract #1491.
Mamounas E, Tang G, Bryant J, Paik S, Shak S, Costantino J, Watson D, Wickerham DL, Wolmark N., Association Between
   the 21-Gene Recurrence Score Assay (RS) and Risk of Loco-Regional Failure in Node-Negative, ER-Positive Breast
   Cancer: Results From NSABP B-14 and NSABP B-20, Presented at: 28th Annual San Antonio Breast Cancer Symposium.
   December 8-11, 2005. San Antonio, TX. Abstract #29.
Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner R, Walker M, Watson D, Bryant J, Wolmark N., Risk
   Classification of Breast Cancer Patients by the Recurrence Score Assay: Comparison to Guidelines Based On Patient Age,
   Tumor Size, and Tumor Grade, Presented at: 27th Annual San Antonio Breast Cancer Symposium. December 8-11, 2004.
   San Antonio, TX. Abstract #104.
Future Trends for Bioinformatics Companies, Kellogg Biotechnology Conference, Sponsored by the Kellogg School of
   Management, Northwestern University, April 2001.
cDNA Based Microarray Technology and Performance, Research Presentation, FDA/Industry Workshop on Microarray
   Technology, Sponsored by the Bay Area Biosciences Center, Stanford University, CA, May 17th, 2000.
Data Mining in the Genomics Revolution, Keynote Speaker, American Statistical Association Spring 2000 Conference,
   Sponsored by the American Statistical Association, Wilmington, DE, April 28th, 2000.
Statistical Methods for Molecular Diagnostics, Invited Speaker, Joint Meetings of the American Statistical Association,
   Anaheim, CA, August 11th, 1997.
Strategies of Research, Invited Speaker, Genentech Inc., Sponsored by the San Francisco Chapter of the American
     Statistical Association, San Francisco, CA, April, 1995.


         1950 Noel Drive • Los Altos, California 94024 • Home (650) 962 -9444
   Cell (650) 888-7302 • e-mail Drew@Novationbio.com • Web: www.DrewWatson.com

                                                      PAGE 4 OF 5
  Drew Watson, Ph.D., MBA


PATENTS
US Patent : Tissue Specific Genes of Diagnostic Import.
US Patent Application 60/375,251: Microarray Performance Management System.
U.S. Provisional patent Application Serial No. 60/810,077: Gene Expression Markers for Colorectal Cancer

COMPUTER SKILLS
Packages: SAS, S-Plus, R, BMDP, SPSS, IMSL, GAUSS, LISP-Stat, GLIM, Mathematica, BMDS, StatXact, LogXact,
          Egret, East, ECHIP, Design-Ease, Statistica, SAS JMP, Resampling Stats, Maple, CART, MARS, Minitab,
          Spotfire
Languages: FORTRAN, C/C++, Visual Basic, SQL
Operating Systems: VAX/VMS, UNIX, MS-DOS, Mac, Windows


SECURITY CLEARANCES
Department of Energy (D.O.E) “Q” (currently inactive).




         1950 Noel Drive • Los Altos, California 94024 • Home (650) 962 -9444
   Cell (650) 888-7302 • e-mail Drew@Novationbio.com • Web: www.DrewWatson.com

                                                      PAGE 5 OF 5

				
DOCUMENT INFO
Shared By:
Categories:
Tags:
Stats:
views:8
posted:7/27/2012
language:
pages:5